How to research a manufacturer across FDA names
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Medical-device intelligence
Research Biomerieux S.A. in public FDA records: applicant and recalling-firm names, product codes, clearance history, and recall records.
This profile groups matching applicant and recalling-firm names found in covered FDA records. It does not imply a complete corporate family, current ownership, or every product marketed under a brand.
16 clearance records and 0 recall records in the covered releases, across 1 source company names and 6 product codes. Dated history runs from May 16, 2011 to Apr 30, 2025.
| Month | 510(k) decisions | Recall initiations |
|---|---|---|
| October 2025 | 0 | 0 |
| November 2025 | 0 | 0 |
| December 2025 | 0 | 0 |
| January 2026 | 0 | 0 |
| February 2026 | 0 | 0 |
| March 2026 | 0 | 0 |
| April 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| June 2026 | 0 | 0 |
| July 2026 | 0 | 0 |
| August 2026 | 0 | 0 |
| September 2026 | 0 | 0 |
| October 2026 | 0 | 0 |
| Device / record | Company in FDA record | Source | Source date |
|---|---|---|---|
| ETEST Imipenem/Relebactam P. aeruginosa (IRPA) (0.008/4-128/4 µg/mL)K250274 · JWY | Biomerieux S.A. | 510(k) | Apr 30, 2025FDA decision date |
| ETEST Fosfomycin (FO) (0.032-512 µg/mL)K210757 · JWY | Biomerieux S.A. | 510(k) | Nov 12, 2021FDA decision date |
| ETEST Delafloxacin (DFX) (0.002-32 µg/mL)K192738 · JWY | Biomerieux S.A. | 510(k) | Nov 26, 2019FDA decision date |
| ETEST Eravacycline (ERV) (0.002 32 µg/mL)K192050 · JWY | Biomerieux S.A. | 510(k) | Sep 27, 2019FDA decision date |
| ETEST Imipenem/Relebactam (IPR) (0.002/4-32/4 ug/mL)K191953 · JWY | Biomerieux S.A. | 510(k) | Aug 22, 2019FDA decision date |
| ETEST Piperacillin/Tazobactam (P/T) (0.016/4-256/4 ug/mL)K190154 · JWY | Biomerieux S.A. | 510(k) | May 1, 2019FDA decision date |
| ETEST Meropenem/Vaborbactam (MEV) (0.004/8-64/8 µg/mL)K183031 · JWY | Biomerieux S.A. | 510(k) | Jan 11, 2019FDA decision date |
| CHROMID CARBA agar (CARB)K181092 · JSO | Biomerieux S.A. | 510(k) | Jul 6, 2018FDA decision date |
| ETEST Telavancin (TLA) (0.002-32 ug/mL)K180936 · JWY | Biomerieux S.A. | 510(k) | Jul 3, 2018FDA decision date |
| RAPIDEC CARBA NPK162385 · PTJ | Biomerieux S.A. | 510(k) | Apr 27, 2017FDA decision date |
| Etest Ceftaroline (0.002 - 32ug/ml)K151873 · JWY | Biomerieux S.A. | 510(k) | Oct 7, 2015FDA decision date |
| VIDAS FT4K132058 · CEC | Biomerieux S.A. | 510(k) | Jun 8, 2015FDA decision date |
| VIDAS C DIFFICILE GDHK132010 · MCB | Biomerieux S.A. | 510(k) | Oct 9, 2013FDA decision date |
| VIDAS LYME IGMK122979 · LSR | Biomerieux S.A. | 510(k) | Jun 4, 2013FDA decision date |
| VIDAS LYME IGGK122986 · LSR | Biomerieux S.A. | 510(k) | Mar 5, 2013FDA decision date |
| ETEST TELAVANCIN IN 0.002-32 UG/ML AND 0.016-256 UG/MLK102535 · JWY | Biomerieux S.A. | 510(k) | May 16, 2011FDA decision date |
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Build a repeatable clearance search using FDA applicant names, product codes, decision dates, and original records.
Read the guide →FDA dataset:
Last successful check: Nov 22, 2026
Source classifications may change.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset monthly.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset weekly.
Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.